ENLV
Price
$1.06
Change
+$0.02 (+1.92%)
Updated
Oct 3 closing price
Capitalization
25.75M
56 days until earnings call
FATE
Price
$1.21
Change
-$0.00 (-0.00%)
Updated
Oct 3 closing price
Capitalization
139.55M
24 days until earnings call
Interact to see
Advertisement

ENLV vs FATE

Header iconENLV vs FATE Comparison
Open Charts ENLV vs FATEBanner chart's image
Enlivex Therapeutics
Price$1.06
Change+$0.02 (+1.92%)
Volume$137.74K
Capitalization25.75M
Fate Therapeutics
Price$1.21
Change-$0.00 (-0.00%)
Volume$5.5M
Capitalization139.55M
ENLV vs FATE Comparison Chart in %
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENLV vs. FATE commentary
Oct 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENLV is a StrongBuy and FATE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 06, 2025
Stock price -- (ENLV: $1.06 vs. FATE: $1.21)
Brand notoriety: ENLV and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENLV: 21% vs. FATE: 312%
Market capitalization -- ENLV: $25.75M vs. FATE: $139.55M
ENLV [@Biotechnology] is valued at $25.75M. FATE’s [@Biotechnology] market capitalization is $139.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENLV’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ENLV’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than ENLV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENLV’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 5 bullish TA indicator(s).

  • ENLV’s TA Score: 4 bullish, 1 bearish.
  • FATE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ENLV is a better buy in the short-term than FATE.

Price Growth

ENLV (@Biotechnology) experienced а +2.91% price change this week, while FATE (@Biotechnology) price change was +21.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

ENLV is expected to report earnings on Dec 01, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($140M) has a higher market cap than ENLV($25.8M). ENLV YTD gains are higher at: -9.402 vs. FATE (-26.667). ENLV has higher annual earnings (EBITDA): -14.21M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. ENLV (19.5M). ENLV has less debt than FATE: ENLV (480K) vs FATE (81.3M). FATE has higher revenues than ENLV: FATE (8.47M) vs ENLV (0).
ENLVFATEENLV / FATE
Capitalization25.8M140M18%
EBITDA-14.21M-161.6M9%
Gain YTD-9.402-26.66735%
P/E RatioN/AN/A-
Revenue08.47M-
Total Cash19.5M223M9%
Total Debt480K81.3M1%
FUNDAMENTALS RATINGS
ENLV vs FATE: Fundamental Ratings
ENLV
FATE
OUTLOOK RATING
1..100
6334
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6146
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is in the same range as ENLV (15) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as ENLV (98) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

FATE's Price Growth Rating (46) in the Biotechnology industry is in the same range as ENLV (61) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENLVFATE
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
76%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 25 days ago
85%
Declines
ODDS (%)
Bearish Trend 11 days ago
89%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FWRG16.260.34
+2.14%
First Watch Restaurant Group
FDX244.612.29
+0.95%
FedEx Corp
DOYU7.44-0.04
-0.53%
DouYu International Holdings Limited
WFRD65.64-0.65
-0.98%
Weatherford International plc
PASG7.95-0.10
-1.24%
Passage Bio Inc

ENLV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENLV has been loosely correlated with APVO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ENLV jumps, then APVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENLV
1D Price
Change %
ENLV100%
+1.92%
APVO - ENLV
39%
Loosely correlated
-1.38%
FATE - ENLV
32%
Poorly correlated
N/A
SLNO - ENLV
29%
Poorly correlated
+2.12%
AXON - ENLV
29%
Poorly correlated
-0.70%
AMRN - ENLV
29%
Poorly correlated
+12.54%
More